- Home
- KRNY vs AVIR Comparison
KRNY vs AVIR Comparison
Compare KRNY & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KRNY | AVIR |
|---|---|---|
| Founded | 1884 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 526.7M | 434.5M |
| IPO Year | 2014 | 2020 |
Fundamental Metrics
Financial Performance| Metric | KRNY | AVIR |
|---|---|---|
| Price | $9.54 | $4.78 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 1 |
| Target Price | $9.25 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 640.6K | 303.4K |
| Earning Date | 04-23-2026 | 05-11-2026 |
| Dividend Yield | ★ 5.45% | N/A |
| EPS Growth | ★ 130.22 | 3.00 |
| EPS | ★ 0.46 | N/A |
| Revenue | $2,580,000.00 | ★ $351,367,000.00 |
| Revenue This Year | $3.89 | N/A |
| Revenue Next Year | $17.52 | N/A |
| P/E Ratio | $20.57 | ★ N/A |
| Revenue Growth | ★ 36.00 | N/A |
| 52 Week Low | $5.76 | $2.78 |
| 52 Week High | $9.48 | $6.45 |
Technical Indicators
Market Signals| Indicator | KRNY | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 75.59 | 57.87 |
| Support Level | $7.36 | $4.14 |
| Resistance Level | N/A | $4.80 |
| Average True Range (ATR) | 0.24 | 0.19 |
| MACD | 0.08 | 0.07 |
| Stochastic Oscillator | 91.70 | 96.19 |
Price Performance
Historical ComparisonAbout KRNY Kearny Financial Corp
Kearny Financial Corp is a federally-chartered stock savings bank. The bank is engaged in the business of attracting deposits from the general public in New Jersey and New York, and using these deposits, together with other funds, to originate or purchase loans for its portfolios and invest in securities. The bank's loan portfolio is chiefly comprised of loans collateralized by commercial and residential real estate. The bank's primary source of income is net interest income.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.